Email this article 
CLINICAL EFFICACY OF EBASTINE IN PATIENTS SUFFERING FROM SPONTANEOUS URTICARIA
- Authors: Elisyutina OG1, Fedenko ES1, Zemskaya EN1, Shtyrbul OV1
-
Affiliations:
- Issue: Vol 13, No 4-5 (2016)
- Pages: 82-87
- Section: Articles
- URL: https://rusalljournal.ru/raj/article/view/402
- DOI: https://doi.org/10.36691/RJA402
- ID: 402
Cite item
Open Access
Access granted
Abstract
Background. To evaluate the efficacy and safety of Kestine® (ebastine) 20 mg sublingual tablets in spontaneous urticaria. Materials and methods. 25 adults suffered from spontaneous chronic urticaria, and 5 patients with acute urticaria aged from 18 to 56 years old (mean age 32,7±10,1) were included in the study. All patients received treatment with Kestine® (ebastine) 20 mg 1 sublingual tab. once daily during 28 days. Assessment of activity and severity of urticaria symptoms was carried out before the treatment, 2 and 4 weeks after the starting of the treatment. To assess the urticaria activity symptoms the urticaria activity score uAS and uAS 7 (for 7 days) were used. Results. The study showed high efficacy and safety of ebastine 20 mg sublingual tablets in the treatment of patients with chronic and acute urticaria. Control under the symptoms was achieved in 20 patients with chronic urticaria (mediana UAS7 before treatment 27 - Q1 - 21, Q3 - 34, after the treatment - 10 - Q1 - 4, Q3 - 12) and in 5 patients with acute urticaria on the 28th day of treatment. Thus Kestine® (ebastine) 20 mg can be recommended as the first line medication in the treatment of spontaneous urticaria.
Keywords
Full Text
About the authors
O G Elisyutina
Institute of Immunology Moscow, Russia
E S Fedenko
Email: efedks@gmail.com
Institute of Immunology Moscow, Russia
E N Zemskaya
Institute of Immunology Moscow, Russia
O V Shtyrbul
Institute of Immunology Moscow, Russia
References
- Cooper K.D. Urticaria and angioedema: diagnosis and evaluation. J. Am. Acad. Dermatol. 1991, v. 25, 166 р.
- Zuberbier T., Asero R., Asero R. et al. The EAACI/GA2LEN/ EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014, v. 69, p. 868-887.
- Ito Y., Satoh T., Takayama K. et al. Basophil recruitment and activation in inflammatory skin diseases. Allergy. 2011, v. 66, p. 1107-1113.
- Greaves M. Chronic urticaria. J. Allergy Clin. Immunol. 2000, v. 105, p. 664-672.
- Walsh G. The clinical relevance of the anti-inflammatory properties of antihistamines. Allergy. 2000, v. 55, p. 53-61.
- Гущин И.С. Холинергическая система и особенности фармакологического вмешательства в нее некоторых антагонистов Н1-рецепторов. Рос. Аллергол. Журн. 2005, № 6, с. 3-16.
- Magerl M.A., Altrichter S., Boodstein N. et al. Urticaria -classification and strategies for diagnosis and treatment. CME Dermatol. 2008, v. 3, p. 2-18.
- Hurst M., Spencer C.M. Ebastine: an update of its use in allergic disorders. Drugs. 2000, v. 59, p. 981-1006.
- Barbanoj M.J., Antonijoan R.M., Garcia-Gea C. et al. Study comparing the inhibitory effects of single and repeated oral doses of ebastine and fexofenadine against histamine-induced skin reactivity. Int. Arch. Allergy Immunol. 2003, v. 132, p. 263-267.
- Ratner P., Hampel F., Gipsert J. Efficacy of ebastine in the control of nasal congestion associated with allergic rhinitis. Methods Find. Exp. Clin. Pharmacol. 2003, v. 25, p. 111-115.
- Magerl M., Schmolke J., Siebenhaar F. et al. Acquired cold urticaria symptoms can be safely prevented by ebastine. Allergy. 2007, v. 62, p. 1465-1468.
- Львов А.Н. Кестин в терапии зудящих дерматозов. Врач. 2004, № 9, с. 54-56.
Supplementary files
